Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry. In today's Pharmaceutical Executive Daily, BioMarin and n-Lorem Foundation partner on the first disease-targeted therapy for the recently identified ReNU syndrome, a trio of biotech financings advance rare disease, sleep apnea, and oncology pipelines, and a Wharton professor offers career advice for MBA graduates navigating an AI-reshaped job market. BioMarin and the n-Lorem Foundation have entered a strategic collaboration and global licensing agreement to develop the first disease-targeted antisense oligonucleotide medicine for ReNU syndrome, a neurodevelopmental disorder identified as a distinct genetic condition only in 2024. ReNU syndrome is projected to affect roughly 100,000 people globally and currently has no approved treatments addressing its underlying cause. Thanks for listening to Pharmaceutical Executive Daily.